Chemoradiotherapy, Adjuvant

• 

  Subject Areas on Research

  • A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group. 
  • A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. 
  • A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma. 
  • A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. 
  • ACR Appropriateness criteria® for nasopharyngeal carcinoma. 
  • ACR appropriateness criteria® nasal cavity and paranasal sinus cancers. 
  • Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). 
  • Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. 
  • Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. 
  • Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. 
  • Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy? 
  • Adjuvant treatment and outcomes for patients with stage IIIA grade 1 endometrioid endometrial cancer. 
  • Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion. 
  • Association Between Incomplete Neoadjuvant Radiotherapy and Survival for Patients With Locally Advanced Rectal Cancer. 
  • Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy. 
  • Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. 
  • Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. 
  • Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience. 
  • Colorectal cancer with potentially resectable hepatic metastases: optimizing treatment. 
  • Dataset for the reporting of carcinoma of the esophagus in resection specimens: recommendations from the International Collaboration on Cancer Reporting. 
  • Defining the Place of Adjuvant Chemotherapy and Radiation for High-Risk Endometrial Cancer From Recent Randomized Clinical Trials: Some Answers, More Questions. 
  • Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? 
  • Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy? 
  • Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. 
  • Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. 
  • FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy. 
  • Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial. 
  • Glioma incidence and survival variations by county-level socioeconomic measures. 
  • Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated Patients. 
  • Impact of Positive Margins on Survival in Patients Undergoing Esophagogastrectomy for Esophageal Cancer. 
  • Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer. 
  • Induction chemoradiation therapy prior to esophagectomy is associated with superior long-term survival for esophageal cancer. 
  • Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer. 
  • International practice survey on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control. 
  • Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma. 
  • Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis? 
  • Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer. 
  • Management of glioblastoma: State of the art and future directions. 
  • Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics. 
  • NCCN Guidelines Insights: Bone Cancer, Version 2.2017. 
  • Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. 
  • Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection. 
  • No Difference in Survival between Neo-Adjuvant Chemotherapy and Neo-Adjuvant Chemoradiation Therapy in Gastric Cardia Cancer Patients: A Contemporary View from the National Cancer Database. 
  • Overall health at diagnosis predicts the risk of complications within the first year after breast cancer diagnosis. 
  • PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer. 
  • Patterns of Failure After Surgery for Non-Small-cell Lung Cancer Invading the Chest Wall. 
  • Patterns of recurrence after ablation of colorectal cancer liver metastases. 
  • Patterns of recurrence after trimodality therapy for esophageal cancer. 
  • Patterns of use and outcomes of sentinel lymph node mapping for patients with high-grade endometrial cancer. 
  • Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. 
  • Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. 
  • Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. 
  • Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. 
  • Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium. 
  • Preoperative radiation therapy in the surgical management of gastric and junctional adenocarcinoma: Should lymph node retrieval guidelines be altered? 
  • Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. 
  • Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer. 
  • Reply to L. Fornaro et al. 
  • Resected irradiated rectal cancers: Are twelve lymph nodes really necessary in the era of neoadjuvant therapy? 
  • Risk factors for surgical site infections after breast surgery: a systematic review and meta-analysis. 
  • Role of Adjuvant Radiotherapy in Locally Advanced Colonic Carcinoma in the Modern Chemotherapy Era. 
  • Role of Chemotherapy and Radiation Therapy in the Management of Gastric Adenocarcinoma. 
  • Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat? 
  • Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. 
  • Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing? 
  • Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis. 
  • Survival outcomes in sinonasal carcinoma with neuroendocrine differentiation: A NCDB analysis. 
  • The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes. 
  • The Role of Adjuvant Therapy in Patients With Margin-Positive (R1) Esophagectomy: A National Analysis. 
  • The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate-risk HPV-negative HNSCC. 
  • The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. 
  • The role of individualized treatment in patients with oesophageal cancer: mind the patient and not only the disease. 
  • Treatment and Outcomes of Women With Large Locally Advanced Breast Cancer. 
  • Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. 
  • VATS versus open surgery for lung cancer resection: moving toward a minimally invasive approach. 
  • Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck. 
• 

  Keywords of People

  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Zafar, Syed Yousuf, Adjunct Professor in the Department of Medicine, Duke Science & Society